Copanlisib, a pan-PI3K inhibitor with PI3Kα and δ activity has clinical activity in follicular lymphoma and has been evaluated in ABC-DLBCL [10, 11]. The gene discussed is PIK3CA; the disease is diffuse large B-cell lymphoma.